If you have been reading about ESI-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | C18 column, water-acetonitrile gradient |
| Detection wavelength | 214 nm, optionally 280 nm | Amide backbone and aromatic side chains |
| Identity confirmation | Electrospray ionisation mass spectrometry | Deconvoluted mass compared with theory |
| Storage of solid | -20 °C or lower, dry and dark | Stability depends on residual moisture |
| Storage in solution | 2-8 °C, short term | Freeze-thaw cycling avoided |
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
No significant changes in HbA1c were observed in the control group (Group B) between baseline (7.1%) and the end of the control lessons (7.0%). The number of 'hypos' decreased significantly from 31 to 14 in Group A (p = 0.03) after AIDA lessons, but did not change significantly in Group B from baseline (n = 20) to after the control lessons (n = 22). Full details of the study and the results can be found in the medical / diabetes literature. The study authors concluded that "larger trials involving more patients in more centres are clearly needed, but this proof-of-concept (pilot) study does demonstrate the feasibility of using a prospective randomised controlled trial approach for the evaluation of educational diabetes simulation software such as AIDA".
=== EC 1.18.1 With NAD+ or NADP+ as acceptor === EC 1.18.1.1: rubredoxin—NAD+ reductase EC 1.18.1.2: ferredoxin—NADP+ reductase EC 1.18.1.3: ferredoxin—NAD+ reductase EC 1.18.1.4: rubredoxin—NAD(P)+ reductase EC 1.18.1.5: Putidaredoxin—NAD+ reductase EC 1.18.1.6: adrenodoxin-NADP+ reductase EC 1.18.1.7: ferredoxin—NAD(P)+ reductase (naphthalene dioxygenase ferredoxin-specific) EC 1.18.1.8: Now EC 7.2.1.2, ferredoxin—NAD+ oxidoreductase (Na+-transporting)
According to the 1996 edition of Vogel's Textbook, yields close to 100% are called quantitative, yields above 90% are called excellent, yields above 80% are very good, yields above 70% are good, yields above 50% are fair, and yields below 40% are called poor. In their 2002 publication, Petrucci, Harwood, and Herring wrote that Vogel's Textbook names were arbitrary, and not universally accepted, and depending on the nature of the reaction in question, these expectations may be unrealistically high. Yields may appear to be 100% or above when products are impure, as the measured weight of the product will include the weight of any impurities. In their 2016 laboratory manual, Experimental Organic Chemistry, the authors described the "reaction yield" or "absolute yield" of a chemical reaction as the "amount of pure and dry product yielded in a reaction". They wrote that knowing the stoichiometry of a chemical reaction—the numbers and types of atoms in the reactants and products, in a balanced equation "make it possible to compare different elements through stoichiometric factors." Ratios obtained by these quantitative relationships are useful in data analysis.
Small-flowered Division: Flowers (1.5–)2–12(–18) cm across Armandii Group: Cultivars belonging to, or derived from, species classified in subsection Meyenianae (Tamura) M. Johnson, mainly C. armandii. Atragene Group: Cultivars belonging to, or derived from, species classified in subgenus Atragene (L.) Torrey & A. Gray, such as C. alpina, C. chiisanensis, C. fauriei, C. koreana, C. macropetala, C. ochotensis, C. sibirica, C. turkestanica. The former Alpina Group and Macropetala Group are included here. Historically, the Alpina Group was used for single-flowered cultivars, and double-flowered cultivars were assigned to the Macropetala Group. Cirrhosa Group: Cultivars belonging to, or derived mainly from, C. cirrhosa. Flammula Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Flammula DC. (excluding subsection Meyenianae (Tamura)M. Johnson), such as C. angustifolia, C. flammula, C. recta, C. terniflora. Forsteri Group: Cultivars belonging to, or derived from, species classified in section Novae-zeelandiae M. Johnson (native to Australia and New Zealand) such as C. australis, C. foetida, C. forsteri, C. marata, C. marmoraria, C. paniculata, C. petriei. Heracleifolia Group: Cultivars with at least one parent belonging to, or derived from, species classified in subgenus Tubulosa (Decne.) Grey-Wilson, such as C. heracleifolia, C. stans, C. tubulosa. Integrifolia Group: Cultivars belonging to, or derived mainly from, C. integrifolia. Includes the Diversifolia Group (which covered C. × diversifolia (C. integrifolia × C.
Sources: en.wikipedia.org
While the initial consolidation of Air Force laboratories reduced overhead and budgetary pressure, another push towards a unified laboratory structure came in the form of the National Defense Authorization Act for Fiscal Year 1996, Section 277. This section instructed the Department of Defense to produce a five-year plan for consolidation and restructuring of all defense laboratories. The currently existing laboratory structure was created in October 1997 through the consolidation of Phillips Laboratory headquartered in Albuquerque, New Mexico, Wright Laboratory in Dayton, Ohio, Rome Laboratory (formerly Rome Air Development Center) in Rome, New York, and Armstrong Laboratory in San Antonio, Texas and the Air Force Office of Scientific Research (AFOSR). The single laboratory concept was developed and championed by Maj Gen Richard Paul, who was Director of Science & Technology for AFMC and Gen Henry Viccellio Jr, and then became the first Commander of AFRL.
There are no widely accepted functions for the resulting truncated RNA transcripts. However, a study in 1981 found evidence that there was a relationship between the number of abortive transcripts produced and the time until long RNA strands are successfully produced. When RNA polymerase undergoes abortive transcription in the presence of ATP, UTP, and GTP, a complex is formed that has a much lower capacity for abortive recycling and a much higher rate of synthesis of the full-length RNA transcript. A study in 2010 found evidence that these truncated transcripts inhibit termination of RNA synthesis by a RNA hairpin-dependent intrinsic terminator. Oligonucleotide Eukaryotic transcription Bacterial transcription
Furazolidone is a nitrofuran antibacterial agent and monoamine oxidase inhibitor (MAOI). It is marketed by Roberts Laboratories under the brand name Furoxone and by GlaxoSmithKline as Dependal-M. Furazolidone has been used in human and veterinary medicine. It has a broad spectrum of activity, being active against: Gram-positive bacteria Clostridium perfringens Corynebacterium pyogenes Streptococci Staphylococci Gram-negative bacteria Escherichia coli Salmonella dublin Salmonella typhimurium Shigella Protozoa Giardia lamblia Eimeria species Histomonas meleagridis
Sources: en.wikipedia.org
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.
Chromatography separates components but does not identify them. Mass measurement gives an independent check that the main peak corresponds to the expected molecular mass. Used together, the two techniques detect both impurity load and structural misassignment.
Hydrolysis and oxidation are the main degradation routes in aqueous media. Loss of the C-terminal amide and oxidation of the aromatic residues are commonly reported changes. Cool storage and short working periods limit the extent of both processes.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.